Welcome to our dedicated page for Lipocine SEC filings (Ticker: LPCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. filed an 8-K stating it issued a press release announcing presentation of LPCN 2401 clinical data at ObesityWeek in Atlanta, GA, held November 4–7. The company furnished the press release as Exhibit 99.1, incorporating it by reference. This is a disclosure of a scientific presentation and does not detail financial metrics or transactions.
Lipocine Inc. filed a current report describing a new press release about the company’s drug candidate LPCN 1154. The release provides a progress update on the ongoing Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The report itself does not detail the trial results or timelines but directs readers to the attached press release, which is included as an exhibit and incorporated by reference.
Lipocine Inc. reported that it has updated the corporate presentation it uses with investors, analysts and other audiences. The update reflects the current status of LPCN 2401, a program being developed as an adjunct to GLP-1 therapy.
The company has received IND clearance to proceed with a proof-of-concept study of LPCN 2401, but is first seeking regulatory clarity on the development path, including study endpoints such as functional loss, before moving forward with the study. The revised investor presentation has been filed as Exhibit 99.1 to this report.
Lipocine Inc. filed a current report to announce that the company will present and meet with investors at the H.C. Wainwright 27th Annual Global Investor Conference. The event is scheduled for September 8–10, 2025, in New York City. The company furnished a press release with additional details as Exhibit 99.1 to the report.
Lipocine Inc. filed an 8-K reporting a material event: the company submitted a presentation as Exhibit 99.1 for the H.C. Wainwright 27th Annual Global Investor Conference and included the interactive cover page Exhibit 104 in Inline XBRL format. The filing is signed by Mahesh V. Patel, President and Chief Executive Officer, and is dated September 5, 2025. The filing does not include earnings, financial tables, or other material transaction disclosures; it documents public investor-facing presentation materials being made available.
Lipocine Inc. reported that scientific abstracts related to its program designated LPCN 2101 have been accepted for presentation at the 2025 American Epilepsy Society annual meeting. The conference is scheduled for December 5–9, 2025, in Atlanta, Georgia. Lipocine furnished the related press release as Exhibit 99.1 to this report.
Lipocine Inc. (LPCN) – Q2 2025 10-Q snapshot
For the quarter ended 30 Jun 2025, revenue jumped to $0.623 M (vs $0.090 M LY) on a one-time $0.5 M license payment from newly signed partners, offsetting lower royalties. Operating expenses fell 10% YoY to $3.0 M, led by a 41% drop in G&A, but R&D rose 14% to support LPCN 1154 and other pipeline programs. Net loss narrowed to $2.21 M (-$0.41 EPS) from -$3.07 M (-$0.57 EPS).
Six-month results were weaker: revenue fell 91% YoY to $0.717 M as the prior-year period contained a $7.5 M Verity up-front; net loss swung to $4.07 M (-$0.76 EPS) from a $0.45 M profit. Operating cash burn was $3.9 M; cash & treasury bills ended at $18.6 M (cash $6.0 M, securities $11.9 M) versus $22.5 M 12/31/24. Management projects liquidity through at least Aug 2026 but continues to access an ATM facility (23,739 shares sold for $0.08 M during Q2).
- Total liabilities remain low at $1.45 M; equity fell to $17.1 M.
- New Aché license (Brazil) plus earlier SPC (South Korea) and Pharmalink (GCC) deals expand TLANDO ex-US footprint; up to $259 M in contingent milestones remain unrealized.
- Authorized shares cut to 75 M; 5.42 M shares outstanding.
- No warrants outstanding after 2019/2020 series expired.
Outlook: Near-term revenue hinges on additional license milestones and TLANDO royalties; continued pipeline spend and limited cash generation imply further equity or partnership funding before 2026.
On 9 July 2025 Lipocine Inc. (NASDAQ: LPCN) filed a Form 8-K under Item 8.01 – Other Events. The sole disclosure is that the company hosted a virtual key-opinion-leader (KOL) event focused on LPCN 1154 (BRLIZIO™) as a potential treatment for postpartum depression. A webcast link and slide deck are available on the corporate website, and the materials have been furnished as Exhibit 99.1.
Under Item 9.01 the filing lists Exhibit 104 (Inline XBRL cover page). No financial metrics, clinical trial results, or transactional details accompany the notice. The document is signed by President & CEO Mahesh V. Patel.
This 8-K signals continued development and external engagement around LPCN 1154 but provides no new quantitative data likely to affect near-term valuation.